CRP and meningeal tuberculosis: Given the meager (approximately 5%) overall survival benefit conferred by dexamethasone in HIV-associated TBM [7] and the known heterogeneity of immune response in this population, it may be valid to evaluate CRP-directed corticosteroids in HIV-associated TBM as the next step.